October 28, 2010 (San Antonio, Texas) — A delayed-release formulation of the anti-inflammatory drug mesalamine showed efficacy in the treatment of diverticulitis at 12 weeks and continued ...

The mechanism of action of mesalamine is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites ...

However, compliance rates are low. Ford et al. conducted a meta-analysis to investigate whether once-daily dosing with mesalamine, which might improve compliance, is as effective as conventional ...

November 3, 2009 (San Diego, California) — In clinical trial results that surprised even the investigators, delayed-release mesalamine (Asacol HD, Procter & Gamble) once a day was as effective ...

The medicine in each brand of mesalamine is the same, but the delivery method is different. Delayed-release tablets and capsules don't release the medicine until they reach your intestine ...

Of the patients receiving Lialda 2.4 g/day (n=343) administered once daily, 83.7% maintained remission at Month 6, which was similar to that seen using the comparator, mesalamine delayed-release 1 ...

June 7 (Reuters) - Cadila Healthcare Ltd: * Says Zydus Cadila gets USFDA final approval for Mesalamine delayed-release tablets USP, 1.2 g. Sign up here. * Says product will be manufactured at the ...

Shire announced that Lialda (mesalamine delayed-release tablets) has been approved for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a ...

Treatment with mesalamine was resumed. Dr. Sporn: The next month, while doing heavy housework, the patient had new dyspnea and bilateral pleuritic chest-wall pain that was greater on the left side ...

The USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA ...